748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
- Resource Type
- Abstract
- Source
- In
Annals of Oncology October 2023 34 Supplement 2:S512-S513 - Subject
- Language
- ISSN
- 0923-7534